For the latest updates and guidance on COVID-19, please consult the Public Health Agency of Canada.
As our country deals with the COVID-19 situation, CADTH has implemented several initiatives to mitigate the risks to our staff and ensure that we continue to support Canada’s health care decision-makers during this period.
Public health authorit...
A new project on Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women is now available for feedback from all interested stakeholders.
Drugs for the Treatment and Prevention of Osteoporosis in Postmenopausal Women
Call for Feedback: 2020-03-05
Feedback Due By: 2020-03-19
Consultation Document: Clinical Report
Today, CADTH has issued final recommendations for:
Indications: transthyretin-mediated amyloidosis
Recommendation: Reimburse with clinical criteria and/or conditions
For more information
A new project on Rituximab to Treat Primary Membranous Nephropathy is now available for feedback from all interested stakeholders.
Rituximab to Treat Primary Membranous Nephropathy
Call for Feedback: 2020-02-13
Feedback Due By: 2020-02-28
Consultation Document: Proposed Project Scope
Product Type: Health Technology Assessment
Read this month’s issue of New at CADTH. Here, you’ll find the latest information on our products and services, corporate news, and news flashes of upcoming events across Canada.